Primary hyperaldosteronism medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 56: | Line 56: | ||
* Acts on distal renal tubule where it selectively blocks sodium transport, leading to inhibition of sodium-potassium exchange<ref name="pmid6927605">{{cite journal |vauthors=Vidt DG |title=Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic |journal=Pharmacotherapy |volume=1 |issue=3 |pages=179–87 |year=1981 |pmid=6927605 |doi= |url= |issn=}}</ref> | * Acts on distal renal tubule where it selectively blocks sodium transport, leading to inhibition of sodium-potassium exchange<ref name="pmid6927605">{{cite journal |vauthors=Vidt DG |title=Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic |journal=Pharmacotherapy |volume=1 |issue=3 |pages=179–87 |year=1981 |pmid=6927605 |doi= |url= |issn=}}</ref> | ||
| | | | ||
* Initial dose: 5 mg OD | |||
* Maintenance dose: 5-10 mg OD<ref name="urlAmiloride Dosage Guide with Precautions - Drugs.com">{{cite web |url=https://www.drugs.com/dosage/amiloride.html |title=Amiloride Dosage Guide with Precautions - Drugs.com |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | |||
| | | | ||
** Nausea, | |||
** Vomiting | |||
** stomach or abdominal pain | |||
** Anorexia | |||
** Bloating, | |||
** Diarrhea | |||
** Headache | |||
** Dizziness | |||
** Skin rash | |||
** Weakness | |||
** Fatigue | |||
** Constipation | |||
** Muscle cramps | |||
** Cough | |||
** Dyspnea | |||
|- | |- | ||
|Calcium channel blockers | |Calcium channel blockers | ||
| Line 74: | Line 91: | ||
| | | | ||
| | | | ||
| | |||
|- | |||
|Dexamethasone therapy(For familial hyperaldosteronism type I) | |||
| | |||
| | |||
| | |||
* 0.5mg-0.75mg OD | |||
| | | | ||
|} | |} | ||
Revision as of 16:53, 10 July 2017
|
Primary hyperaldosteronism Microchapters |
|
Differentiating Primary Hyperaldosteronism from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary hyperaldosteronism medical therapy On the Web |
|
American Roentgen Ray Society Images of Primary hyperaldosteronism medical therapy |
|
Risk calculators and risk factors for Primary hyperaldosteronism medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The optimal therapy for primary hyperladosteronism depends on the etiology of hyperaldosteronism.
Medical Therapy
Medical therapy is indicated for bilateral adrenal hyperplasia and all ambiguous causes of primary hyperaldosteronism. The following agents may be used to medical management of primary hyperaldosteronism:
| Drug Class | Agents | Mechanism of action | Dosage | Side effects |
|---|---|---|---|---|
| Mineralocorticoid receptor antagonists | Spironolactone |
|
|
|
| Potassium canrenoate |
|
|||
| Eplerenone |
|
50 mg OD[2] |
| |
| Potassium-sparing diuretics |
|
|
|
|
| Calcium channel blockers | ||||
| ACE inhibitors | ||||
| Angiotensin receptor blockers | ||||
| Dexamethasone therapy(For familial hyperaldosteronism type I) |
|
- ↑ "www.accessdata.fda.gov" (PDF).
- ↑ Craft J (2004). "Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure". Proc (Bayl Univ Med Cent). 17 (2): 217–20. PMC 1200656. PMID 16200104.
- ↑ Vidt DG (1981). "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic". Pharmacotherapy. 1 (3): 179–87. PMID 6927605.
- ↑ "Amiloride Dosage Guide with Precautions - Drugs.com".